Deborah W. Knapp
YOU?
Author Swipe
View article: Hypoxia-inducible factor 1α expression does not differ between canine urothelial carcinoma and normal urinary bladder tissue
Hypoxia-inducible factor 1α expression does not differ between canine urothelial carcinoma and normal urinary bladder tissue Open
Objective To evaluate the RNA and protein expression of hypoxia-inducible factor (HIF-1α) in canine urothelial carcinoma (UC) compared to normal canine urinary bladder tissue. Methods Dogs with normal urinary bladder tissue were enrolled a…
View article: Characterisation of Gene Expression in Canine Invasive Urothelial Carcinoma Using a <scp>NanoString</scp>‐Based Urine Assay
Characterisation of Gene Expression in Canine Invasive Urothelial Carcinoma Using a <span>NanoString</span>‐Based Urine Assay Open
For human and canine invasive urothelial carcinoma (InvUC), there is growing interest in using the molecular characteristics of a tumour to guide individualised treatment strategies. The objective of this study was to use a non‐invasive, u…
View article: Enhanced HDR-mediated correction of heterozygous COL7A1 mutations for recessive dystrophic epidermolysis bullosa
Enhanced HDR-mediated correction of heterozygous COL7A1 mutations for recessive dystrophic epidermolysis bullosa Open
Gene editing facilitated by homology-directed repair (HDR) holds great potential for treating monogenetic disorders such as recessive dystrophic epidermolysis bullosa (RDEB). However, low efficiency and variability between loci must be ove…
View article: Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark
Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark Open
Correctly identifying perturbed biological pathways is a critical step in uncovering basic disease mechanisms and developing much-needed therapeutic strategies. However, whether current tools are optimal for unbiased discovery of relevant …
View article: Genome-wide analyses reveals an association between invasive urothelial carcinoma in the Shetland sheepdog and NIPAL1
Genome-wide analyses reveals an association between invasive urothelial carcinoma in the Shetland sheepdog and NIPAL1 Open
View article: Association between cigarette smoke exposure and urinary bladder cancer in Scottish terriers in a cohort study
Association between cigarette smoke exposure and urinary bladder cancer in Scottish terriers in a cohort study Open
Canine urothelial carcinoma (UC) initially responds favorably to treatment, but is ultimately lethal in most cases. Research to identify modifiable risk factors to prevent the cancer is essential. The high breed-associated risk for UC, e.g…
View article: Genome-wide analyses reveals an association between invasive urothelial carcinoma in the Shetland sheepdog, NIPAL1, and the MAPK signaling pathway
Genome-wide analyses reveals an association between invasive urothelial carcinoma in the Shetland sheepdog, NIPAL1, and the MAPK signaling pathway Open
Naturally occurring canine invasive urinary carcinoma (iUC) closely resembles human muscle invasive bladder cancer in terms of histopathology, metastases, response to therapy and, low survival rate. The heterogeneous nature of the disease …
View article: Leading the pack: Best practices in comparative canine cancer genomics to inform human oncology
Leading the pack: Best practices in comparative canine cancer genomics to inform human oncology Open
Pet dogs develop spontaneous cancers at a rate estimated to be five times higher than that of humans, providing a unique opportunity to study disease biology and evaluate novel therapeutic strategies in a model system that possesses an int…
View article: Tumor cell-derived lactic acid inhibits the interaction of PD-L1 protein and PD-L1 antibody in the PD-L1/PD-1 blockade therapy-resistant tumor
Tumor cell-derived lactic acid inhibits the interaction of PD-L1 protein and PD-L1 antibody in the PD-L1/PD-1 blockade therapy-resistant tumor Open
Immune checkpoint blockade therapy targeting the PD-1/PD-L1 axis has shown remarkable clinical impact in multiple cancer types. Nontheless, despite the recent success of PD-1/PD-L1 blockade therapy, such response rates in cancer patients h…
View article: cTULIP: application of a human-based RNA-seq primary tumor classification tool for cross-species primary tumor classification in canine
cTULIP: application of a human-based RNA-seq primary tumor classification tool for cross-species primary tumor classification in canine Open
Introduction The domestic dog, Canis familiaris , is quickly gaining traction as an advantageous model for use in the study of cancer, one of the leading causes of death worldwide. Naturally occurring canine cancers share clinical, histolo…
View article: FIGURE 2 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
FIGURE 2 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
The high-throughput screening of therapeutic antibodies. A, Schematic diagram of the cPD-L1 antibody binding assay. BT549 cells expressing cPD-L1 were seeded on 96-well or 384-well plates. cPD-L1 antibodies (from hybridomas) and Ale…
View article: FIGURE 5 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
FIGURE 5 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
Evaluation of the caninized cPD-L1 chimeric antibody. A, 12C antibody binding on the BT549cPD-L1 cells. B, Flow cytometric analysis of the 12C chimeric antibody on the BT549cPD-L1 cells. cIgG serves as a…
View article: Data from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
Data from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
Immune checkpoint blockade therapy, one of the most promising cancer immunotherapies, has shown remarkable clinical impact in multiple cancer types. Despite the recent success of immune checkpoint blockade therapy, however, the response ra…
View article: FIGURE 2 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
FIGURE 2 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
The high-throughput screening of therapeutic antibodies. A, Schematic diagram of the cPD-L1 antibody binding assay. BT549 cells expressing cPD-L1 were seeded on 96-well or 384-well plates. cPD-L1 antibodies (from hybridomas) and Ale…
View article: FIGURE 3 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
FIGURE 3 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
cPD-L1 antibodies enhance antitumor immunity in the caninized PD-L1 syngeneic mouse model. A, Knock-in strategy of the caninized PD-L1 mice (c57BL/c background). B, Validation of cPD-L1 protein expression in the MB49cPD-…
View article: FIGURE 6 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
FIGURE 6 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
Pharmacokinetic analysis of 12C chimeric antibody in laboratory dogs. A, Schematic diagram of ELISA for pharamacokinetic analysis. The concentration of the 12C chimeric antibody was measured in the 2 mg/kg (B) or 5 mg/kg (…
View article: Data from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
Data from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
Immune checkpoint blockade therapy, one of the most promising cancer immunotherapies, has shown remarkable clinical impact in multiple cancer types. Despite the recent success of immune checkpoint blockade therapy, however, the response ra…
View article: FIGURE 6 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
FIGURE 6 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
Pharmacokinetic analysis of 12C chimeric antibody in laboratory dogs. A, Schematic diagram of ELISA for pharamacokinetic analysis. The concentration of the 12C chimeric antibody was measured in the 2 mg/kg (B) or 5 mg/kg (…
View article: FIGURE 5 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
FIGURE 5 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
Evaluation of the caninized cPD-L1 chimeric antibody. A, 12C antibody binding on the BT549cPD-L1 cells. B, Flow cytometric analysis of the 12C chimeric antibody on the BT549cPD-L1 cells. cIgG serves as a…
View article: TABLE 1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
TABLE 1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
Summary of potential adverse events with the initial cPD-L1 antibody administration to laboratory dogs
View article: Table S1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
Table S1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
The list of genes that were altered in the activated canine PBMCs from the nCounter canine immune-oncology panel analysis
View article: FIGURE 3 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
FIGURE 3 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
cPD-L1 antibodies enhance antitumor immunity in the caninized PD-L1 syngeneic mouse model. A, Knock-in strategy of the caninized PD-L1 mice (c57BL/c background). B, Validation of cPD-L1 protein expression in the MB49cPD-…
View article: FIGURE 1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
FIGURE 1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
Working flow chart for production and validation of the cPD-L1 antibody. A, Immunization of antigen, cPD-L1 protein. B, Establishment of hybridomas (over 2,000 clones). C, Evaluation of the cPD-L1 specific antibody by …
View article: FIGURE 4 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
FIGURE 4 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
The quality attributes of the purified anti-cPD-L1, 1210E4 (12C) chimeric antibody. A, Canine PD-L1, 12C10E4 chimeric antibody expression construct, pTRIOZ-cIgG2-cPD-L1 12C10E4. B, SDS-PAGE analysis of 12C chimeric antibody p…
View article: TABLE 1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
TABLE 1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
Summary of potential adverse events with the initial cPD-L1 antibody administration to laboratory dogs
View article: FIGURE 1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
FIGURE 1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
Working flow chart for production and validation of the cPD-L1 antibody. A, Immunization of antigen, cPD-L1 protein. B, Establishment of hybridomas (over 2,000 clones). C, Evaluation of the cPD-L1 specific antibody by …
View article: Table S1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
Table S1 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
The list of genes that were altered in the activated canine PBMCs from the nCounter canine immune-oncology panel analysis
View article: FIGURE 4 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
FIGURE 4 from Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
The quality attributes of the purified anti-cPD-L1, 1210E4 (12C) chimeric antibody. A, Canine PD-L1, 12C10E4 chimeric antibody expression construct, pTRIOZ-cIgG2-cPD-L1 12C10E4. B, SDS-PAGE analysis of 12C chimeric antibody p…
View article: Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans
Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans Open
Immune checkpoint blockade therapy, one of the most promising cancer immunotherapies, has shown remarkable clinical impact in multiple cancer types. Despite the recent success of immune checkpoint blockade therapy, however, the response ra…
View article: Supplementary Tables 2 and 3 from Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer—Evidence for a Relevant Model System and Urine-Based Diagnostic Test
Supplementary Tables 2 and 3 from Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer—Evidence for a Relevant Model System and Urine-Based Diagnostic Test Open
Supplementary Tables 2 and 3. Listing genotypes and clinical data.